MURATA-MANUFACTURING
14.5.2024 05:01:33 CEST | Business Wire | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) unveils a significant advancement in the realm of electronic components with the launch of its innovative L Cancel Transformer (LCT). This remarkable product is the first of its kind and can neutralize the equivalent series inductance (ESL) of a capacitor, optimizing its noise-reducing capabilities. Utilizing Murata’s exclusive ceramic multilayer technology, this breakthrough solution allows engineers to reduce system noise while decreasing costs and component count.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513693449/en/
[Murata Manufacturing Co., Ltd.] L Cancel Transformer(Photo: Business Wire)
As the demand for miniaturized and highly functional electronics increases, the issue of electromagnetic noise is becoming increasingly prominent for many industries. As a noise countermeasure, capacitors are often utilized between the power supply line and ground, but this method is not without its challenges. The noise removal effectiveness of the capacitor is optimal when a capacitor’s impedance is lowest. However, capacitor impedance can rise due to its ESL, particularly at frequencies beyond the self-resonant frequency, undermining the efficacy of the noise cancellation. To minimize this impact, it is common practice to connect numerous capacitors in parallel in order to collectively reduce impedance, at the expense of Bill of Material (BoM) component count and costs.
Murata’s LCT is a revolutionary new concept capable of resolving the longstanding challenge of managing power supply noise and capacitor component count. Murata’s LCT component is specifically engineered to minimize noise within the frequency range of a few MHz to 1GHz. It achieves this by utilizing negative mutual inductance to reduce a noise-reducing capacitor’s ESL and therefore increase the effectiveness of its operation, drastically reducing the number of required capacitors.
By using non-magnetic ceramic multilayer technology in its construction, the LCT ensures stable negative inductance and low DC resistance (maximum 55mΩ) even in the presence of current variations and is suitable for a wide range of applications, including consumer, industrial and healthcare products. Murata’s LCT breakthrough is a result of their extensive multilayer ceramic knowledge and redefines power supply noise reduction circuit design, and minimizes a significant and persistent electronic design challenge.
Each LCT is suitable for temperatures up to temperatures 125oC and since there is no DC superposition characteristic, it can be used with stable negative inductance up to 3A. The surface mount device (SMD) measures just 2.0 x 1.25 x 0.95 mm and is available in tape and reel packing.
“Murata’s new LCT is a true innovation that does not merely improve what is available, but redefines what is seen as a standard noise suppression component by radically redefining the entire concept”, said Masamichi Ando, Vice President Business Incubation Center Corporate Technology & Business Development Unit, at Murata. “With this revolutionary component, engineers will be able to reduce component count, system complexity and costs, helping to both further miniaturize their solutions and reduce its impact on the environment by lowering material consumption.”
Murata’s LCT (Part number: LXLC21HN0N9C0L) is entering production with samples available now. For more information please visit here.
Please contact us for details: contact form
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513693449/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
